Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$80 Mln
Revenue (TTM)
$58 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
19.2
Industry P/E
--
EV/EBITDA
20.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
13,886,826
CFO
$-10.04 Mln
EBITDA
$-33.94 Mln
Net Profit
$-45.65 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Champions Oncology (CSBR)
| -16.5 | -3.1 | -16.5 | -33.0 | 12.8 | -12.7 | 4.8 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Champions Oncology (CSBR)
| -19.4 | 52.0 | 24.6 | -46.1 | -22.5 | 29.5 | 6.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Champions Oncology (CSBR)
|
5.8 | 80.1 | 57.9 | -2.3 | -4.1 | -57 | -- | 19.2 |
| 1.0 | 3.8 | 0.0 | -7.0 | -- | -187.1 | -- | 1.8 | |
| 2.6 | 85.5 | 0.0 | -10.3 | -- | -64.5 | -- | 6.0 |
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based... upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Read more
CEO & Director
Dr. Ronnie Morris M.D.
CEO & Director
Dr. Ronnie Morris M.D.
Headquarters
Hackensack, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Champions Oncology Inc (CSBR) is $5.77 (NASDAQ) as of 02-Apr-2026 16:37 EDT. Champions Oncology Inc (CSBR) has given a return of 12.8% in the last 3 years.
Since, TTM earnings of Champions Oncology Inc (CSBR) is negative, P/E ratio is not available.
The P/B ratio of Champions Oncology Inc (CSBR) is 19.18 times as on 02-Apr-2026, a 382 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Champions Oncology Inc (CSBR) are Rs 9.63 and Rs 5.50 as of 05-Apr-2026.
Champions Oncology Inc (CSBR) has a market capitalisation of $ 80 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Champions Oncology Inc (CSBR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.